Nature’s Sunshine Products (NASDAQ:NATR) and Context Therapeutics (NASDAQ:CNTX) Critical Comparison

Nature’s Sunshine Products (NASDAQ:NATRGet Free Report) and Context Therapeutics (NASDAQ:CNTXGet Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Profitability

This table compares Nature’s Sunshine Products and Context Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nature’s Sunshine Products 4.06% 14.67% 9.27%
Context Therapeutics N/A -59.95% -54.78%

Insider and Institutional Ownership

79.4% of Nature’s Sunshine Products shares are held by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are held by institutional investors. 3.1% of Nature’s Sunshine Products shares are held by insiders. Comparatively, 4.8% of Context Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Nature’s Sunshine Products has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500.

Valuation and Earnings

This table compares Nature’s Sunshine Products and Context Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nature’s Sunshine Products $480.14 million 0.80 $19.52 million $1.10 19.85
Context Therapeutics N/A N/A -$36.12 million ($0.42) -6.74

Nature’s Sunshine Products has higher revenue and earnings than Context Therapeutics. Context Therapeutics is trading at a lower price-to-earnings ratio than Nature’s Sunshine Products, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Nature’s Sunshine Products and Context Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nature’s Sunshine Products 0 0 3 0 3.00
Context Therapeutics 1 0 6 1 2.88

Nature’s Sunshine Products presently has a consensus price target of $35.00, indicating a potential upside of 60.26%. Context Therapeutics has a consensus price target of $6.60, indicating a potential upside of 133.22%. Given Context Therapeutics’ higher probable upside, analysts plainly believe Context Therapeutics is more favorable than Nature’s Sunshine Products.

Summary

Nature’s Sunshine Products beats Context Therapeutics on 9 of the 14 factors compared between the two stocks.

About Nature’s Sunshine Products

(Get Free Report)

Nature’s Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature’s Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature’s Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.

About Context Therapeutics

(Get Free Report)

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Receive News & Ratings for Nature's Sunshine Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nature's Sunshine Products and related companies with MarketBeat.com's FREE daily email newsletter.